BioSpace News Archive

Oncocross, an AI-based drug development biotech, announced that it initiated a phase I global clinical trial for ‘OC514’ targeting muscular diseases including sarcopenia.

Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced today that it has received $2.5M grant as part of National Cancer Institute’s Notice of Special Interest announcement.

Atrion Corporation (NASDAQ: ATRI) today announced its results for the fourth quarter ended December 31, 2021 and the full year 2021.

PacBio announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock, and restricted stock units covering 50,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan effective on February 22, 2022.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding the New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome.